David Alejandro Curiel-Pedraza

David Alejandro Curiel-Pedraza

Auto-generated profile, based on publicly available information

David Alejandro Curiel-Pedraza

Unidad de Biotecnología Médica Farmacéutica , Centro de Investigación y Asistencia en Tecnología y Diseño Del Estado de Jalisco A.C. , Jalisco , Mexico , ciatej.net.mx

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Food Chemistry Advances
Verified
Journal Article
Open access
DCDavid Alejandro Curiel-Pedraza
David Alejandro Curiel-Pedraza
EVElda Cristina Villaseñor-Tapia
Elda Cristina Villaseñor-Tapia
AMAna Laura Márquez-Aguirre
Ana Laura Márquez-Aguirre
CMClaudia Elizabeth Morales-Martínez
Claudia Elizabeth Morales-Martínez
TDTania Diaz-Vidal
Tania Diaz-Vidal
JGJorge Alberto Rodríguez González
Jorge Alberto Rodríguez González

1 January 2026 in Biochemistry Research International
Verified
Journal Article
Open access
PDF file
EVElda Cristina Villaseñor-Tapia
Elda Cristina Villaseñor-Tapia
EMEdgar Ruben Mendieta-Condado
Edgar Ruben Mendieta-Condado
DCDavid Alejandro Curiel-Pedraza
David Alejandro Curiel-Pedraza
EREdwin Estefan Reza-Zaldivar
Edwin Estefan Reza-Zaldivar
AMAna Laura Márquez-Aguirre
Ana Laura Márquez-Aguirre
Metabolic dysfunction–associated steatotic liver disease (MASLD) is defined as the presence of excess triglyceride storage in the liver in the presence of at least one cardiometabolic risk factor. This term highlights the connection between fatty liver and metabolic dysfunction. Dietary factors, such as excessive consumption of saturated fats and sugar, contribute significantly to the accumulation of lipids in organs not specialized for fat storage, such as the liver. Hepatic lipid accumulation initiates dynamic changes in mitochondrial function and promotes the development and progression of MASLD. High‐fat, high‐fructose diet models have provided crucial insights into how nutritional factors induce mitochondrial dysfunction, which is characterized by impaired fatty acid oxidation, excessive generation of reactive oxygen species, and damage to mitochondrial DNA. Lifestyle modifications, including dietary adjustments such as calorie restriction and weight loss, are essential for the early prevention and long‐term treatment of MASLD. However, in recent years, several pharmacological options have emerged for the treatment of MASLD, primarily for the management of its comorbidities. This review explores the mechanisms of mitochondrial dysfunction promoted by the accumulation of hepatic lipids, analyzes the evidence of mitochondrial alterations in the liver of dietary models, and summarizes some of the main therapeutic interventions for MASLD and their effects on mitochondrial function.